Aditx Therapeutics, Inc. Announces the Operational Launch of the AditxtScore™ Immune Monitoring Platform
January 21, 2021 at 01:00 pm
Share
Aditx Therapeutics, Inc. announced the operational launch of the AditxtScore™ Immune Monitoring Platform as of February 1st, 2021. The initial application of the platform will be AditxtScore™ for COVID-19 which has been designed to provide a more complete assessment of an individual’s infection and immunity status with respect to the SARS-CoV-2 virus. Infection status will be determined by evaluating the presence or absence of the virus, and immunity status by measuring levels of antibodies against viral antigens and their ability to neutralize the virus. Aditxt will soon be expanding the panel to measure other components of the immune response such as cellular immunity. AditxtScore™ for COVID-19 will be available as a Lab Developed Test (LDT) and processed at the AditxtScore™ Immune Monitoring Center, which will operate as a CLIA-certified reference lab for the Company’s prospective channel partners, including labs and hospitals.
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
ADITXT, INC. 
